Chicago Cancer Genome Project studies genetics of 1,000 tumors

The project also will gather genetic data on how the genes expressed by tumors evolve over time. Whenever possible, the researchers will compare tumor samples taken from a patient before and after treatments, to learn how cancers accumulate additional genetic changes that enable them to resist radiation or chemotherapy or to spread to distant sites.

Patterns of care in the initial management of women with ovarian cancer in Ontario

Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature

An investigation of patients’ motivations for their participation in genetics-related research

An investigation of patients’ motivations for their participation in genetics-related research

abstract - multinational study: Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers

Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers - abstract - multinational study

Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel

High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.

Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the

open access: Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management

Subjects carrying a mutation in one of the MMR genes have a higher risk for developing colorectal cancer, but also for endometrial carcinoma and malignancies of the stomach, small bowel, ovaries, upper uroepithelial tract, biliary tract, skin and brain.(pancreas)

Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008

More importantly, tumour type and stage of disease are essential for drawing conclusions from such findings.

Carey et al.

2008 244 advanced ovarian cancer EORTC QLQ-C30 Performance status and global QOL scores at baseline were prognostic factors for both progression-free survival and overall survival.

Gupta et al.

2008 90 ovarian cancer Ferrans and Powers QLI No statistically significant prognostic
association of patient satisfaction with QOL was observed with survival.

Imagine someone had been managing your data, and then you looked. | e-Patients.net

Imagine someone had been managing your data, and then you looked. | e-Patients.net

4:15 min video (IP) Improvements in the treatment of advanced ovarian cancer

Addressing the challenge: current and future directions in ovarian cancer therapy.

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper ab

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

The origin of serous ovarian cancer may be found in the uterus: A novel hypothesis

Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: A meta-analysis

Maturitas : Hormone replacement after gynaecological cancer

Maturitas : Hormone replacement therapy (HRT), breast cancer and tumor pathology

Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers - multinational study

Changes in the Mouse Estrus Cycle in Response to Brca1 Inactivation Suggest a Potential Link between Risk Factors for Familial and Sporadic Ovarian Cancer

in research (mice)

A Billion Little Experiments.pdf (application/pdf Object)

some very good points in this article